Business context and reporting period
Interlink Electronics, Inc. (Nasdaq: LINK) filed this Form 10-K for the fiscal year ended December 31, 2022; it is an annual report, not a standalone fourth-quarter report. The company develops and sells force-sensing and human-machine-interface products and, following its December 2022 acquisition of SPEC Sensors and KWJ Engineering, gas-sensing products. The filing reports one operating segment.
Financial results and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $7.493 million | $7.478 million |
| Gross profit / margin | $3.861 million / 51.5% | $4.058 million / 54.3% |
| Operating loss / margin | $(0.668) million / (8.9)% | $(0.079) million / (1.1)% |
| Net income (loss) | $1.672 million | $(0.734) million |
| Net income (loss) per common share, diluted | $0.19 | $(0.12) |
| Cash from (used in) operating activities | $(0.915) million | $0.231 million |
Revenue was nearly unchanged year over year. The reported 2022 profit was substantially affected by non-operating income, principally gains on marketable securities; it did not reflect improved operating profitability. The filing reports $2.611 million of net other income for 2022, including approximately $2.45 million of securities gains. Verify the reported gain amount and reconciliation: the MD&A and cash-flow statement cite $2.449 million, while the marketable-securities note cites realized gains of $2.249 million.
At year-end, cash and cash equivalents were $10.091 million, working capital was $12.6 million, and the company reported no indebtedness. Current assets were $13.702 million and current liabilities $1.089 million. Preferred stock had a $5 million aggregate liquidation preference and an 8% cumulative dividend; $0.400 million of preferred dividends were paid in 2022. Cash declined by approximately $0.691 million during the year.
Material changes versus the prior period
- Gross margin fell 2.8 percentage points. Management attributed the decline to higher material, freight and tariff costs, product and customer mix, and production efficiencies.
- R&D expense rose 36.6% to $1.220 million, reflecting added engineering headcount and development costs; 2021 also included a $0.129 million Singapore research incentive.
- Operating expenses increased to $4.529 million from $4.137 million, contributing to a larger operating loss. The 2021 comparison benefited from $0.186 million of PPP loan forgiveness recorded as an SG&A benefit.
- Medical-market revenue increased 69.2% to $1.865 million, primarily on higher orders from the largest medical customer. Consumer revenue declined 71.4% to $0.363 million, primarily following a major customer’s design change.
- The December 2022 SPEC/KWJ asset acquisition added gas-sensing operations for approximately $2.2 million. The acquired businesses contributed $0.010 million revenue and a $0.100 million loss after acquisition through year-end; purchase accounting remained provisional.
Outlook, risks, and unusual items
Management stated that existing cash was expected to support current operations and known cash requirements for the next twelve months and beyond. The filing provides no numerical revenue or earnings guidance. Strategy centers on expanding existing and new markets, growing customer relationships, developing multi-technology sensing products, and pursuing acquisitions.
Key risks include dependence on a small number of customers without firm long-term purchase commitments, supplier and shipping disruptions, manufacturing concentration in China, competition and pricing pressure, product acceptance and execution risks, and foreign-currency, trade, regulatory, and cybersecurity exposures. The filing also notes the CEO’s and CFO’s roles at other companies, concentrated voting control (the CEO beneficially owned approximately 82% of common stock), and related-party cost-sharing and consulting arrangements.
Subsequent events: approximately $0.8 million of cash was held at Silicon Valley Bank on March 10, 2023, largely uninsured; the company said it continued to expect adequate liquidity. On March 17, 2023, it acquired Calman Technology Limited for approximately $5.0 million. The financial statements received unqualified audit opinions, with no critical audit matters reported. Management said disclosure controls and internal control over financial reporting were effective; the auditor was not required to attest to internal-control effectiveness.
Most important facts for investors to verify
- Reconcile the differing securities-gain figures and assess how much 2022 net income depended on investment gains rather than operations.
- Review cash conversion: operating cash flow was negative despite reported net income, and cash fell during the year.
- Track customer concentration, especially the largest customer’s 24.9% share of 2022 revenue, and the sustainability of medical-market growth.
- Assess the integration, final purchase accounting, and operating contribution of SPEC/KWJ, as well as the funding and effects of the subsequent Calman acquisition.
- Confirm the effect of preferred dividends, the $5 million liquidation preference, and any future financing or dilution needs.
- Monitor uninsured bank deposits, China-related supply and manufacturing exposure, and the company’s customer, supplier, and related-party dependencies.